As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
9 Analysts have issued a Agenus Inc. forecast:
9 Analysts have issued a Agenus Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 102 102 |
36%
36%
|
|
| Gross Profit | 101 101 |
36%
36%
|
|
| EBITDA | -78 -78 |
21%
21%
|
|
| EBIT (Operating Income) EBIT | -91 -91 |
20%
20%
|
|
| Net Profit | -166 -166 |
26%
26%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
| Head office | United States |
| CEO | Garo Armen |
| Employees | 316 |
| Founded | 1994 |
| Website | agenusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


